SCHEMBL2823045

SCHEMBL2823045

Cc1nc2ccc(F)c(F)c2c(OC(=O)C2CC2)c1C

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.33
MEN1 O00255 1/20 0.33
RAB9A P51151 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
ALDH1A1 P00352 3/20 0.32
KDM4E B2RXH2 2/20 0.32
HPGD P15428 1/20 0.32
CASP1 P29466 1/20 0.32
HSD17B10 Q99714 1/20 0.32
MAPT P10636 1/20 0.32
HTT P42858 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
MMP13 P45452 2/20 0.32
PDE2A O00408 1/20 0.32
PDE10A Q9Y233 1/20 0.32
GRM1 Q13255 5/20 0.32
TNKS O95271 1/20 0.31
PARP1 P09874 1/20 0.31
TNKS2 Q9H2K2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2818881 0.88 KDM4E (0.33) KMT2AMEN1RAB9AL3MBTL1ALDH1A1
SCHEMBL2819562 0.86 USP2 (0.37) KMT2AMEN1RAB9AALDH1A1KDM4E
SCHEMBL2823483 0.86 KDM4E (0.32) KMT2AMEN1RAB9AL3MBTL1ALDH1A1
SCHEMBL2820985 0.83 MMP13 (0.34) KMT2AMEN1RAB9AL3MBTL1ALDH1A1
SCHEMBL2820327 0.82 MMP13 (0.32) MMP13TNKSPARP1TNKS2
SCHEMBL2821998 0.82 KMT2A (0.36) KMT2AMEN1RAB9AL3MBTL1ALDH1A1
SCHEMBL2820048 0.81 MMP13 (0.37) KMT2AMEN1ALDH1A1KDM4EMAPT
SCHEMBL2820529 0.80 ALDH1A1 (0.30) ALDH1A1HPGDSMN1; SMN2
SCHEMBL2824191 0.80 MAPT (0.36) KMT2AMEN1RAB9AL3MBTL1ALDH1A1
SCHEMBL2821739 0.79 TSHR (0.34) ALDH1A1KDM4ESMN1; SMN2MMP13TNKS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1386914-B1 HALOGENATED QUINOLINE DERIVATIVES AND ECTOPARASITE CONTROLLERS MEIJI SEIKA KAISHA (JP) 2010-10-27 EP disclosed
US-7022855-B2 Halogen-substituted quinoline derivatives and ectoparasite control agent MEIJI SEIKA KAISHA, LTD. (JP) 2006-04-04 US disclosed
EP-1559321-A1 MIXED COMPOSITIONS FOR CONTROLLING PARASITIC INSECTS MEIJI SEIKA KAISHA LTD. (JP) 2005-08-03 EP disclosed
US-20040087618-A1 Halogen-substituted quinoline derivatives and ectoparasite control agent MEIJI SEIKA KAISHA, LTD. (JP) 2004-05-06 US disclosed
US-20040077602-A1 Mixture composition for controlling ectoparasites MEIJI SEIKA KAISHA, LTD. (JP) 2004-04-22 US disclosed
EP-1386914-A1 HALOGENATED QUINOLINE DERIVATIVES AND ECTOPARASITE CONTROLLERS MEIJI SEIKA KAISHA LTD. (JP) 2004-02-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087618-A1 Halogen-substituted quinoline derivatives and ectoparasite control agent ATL3, RABL3, RAB5C KMT2A 1368/4885MEN1 3131/4885RAB9A 179/4885
US-20040077602-A1 Mixture composition for controlling ectoparasites SF3A3, PEX3, HCN3 KMT2A 1494/4885MEN1 2772/4885RAB9A 569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.